Connie Marras

Summary

Affiliation: University Health Network
Country: Canada

Publications

  1. ncbi request reprint Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the international collaboration on mild traumatic brain injury prognosis
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, and the Edmond J Safra Program in Parkinson s Research, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada Electronic address
    Arch Phys Med Rehabil 95:S238-44. 2014
  2. doi request reprint Measuring mild cognitive impairment in patients with Parkinson's disease
    Connie Marras
    Toronto Western Hospital Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Research, Toronto, Ontario, Canada
    Mov Disord 28:626-33. 2013
  3. pmc Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples
    Connie Marras
    Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
    Neurology 78:1016-24. 2012
  4. doi request reprint Dihydropyridine calcium channel blockers and the progression of parkinsonism
    Connie Marras
    Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada
    Ann Neurol 71:362-9. 2012
  5. doi request reprint Antipsychotics and mortality in Parkinsonism
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, ON, Canada
    Am J Geriatr Psychiatry 20:149-58. 2012
  6. doi request reprint Genetics meets environment: evaluating gene-environment interactions in neurologic diseases
    Connie Marras
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Semin Neurol 31:553-61. 2011
  7. pmc Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers
    C Marras
    Toronto Western Hospital, Edmond J Safra Program in Parkinson s Disease, Toronto, ON M5T 2S8 Canada
    Neurology 77:325-33. 2011
  8. doi request reprint Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 26:608-13. 2011
  9. doi request reprint Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease
    William Reginold
    Toronto Western Hospital, Toronto, Ont, Canada
    Dement Geriatr Cogn Disord 36:67-75. 2013
  10. doi request reprint Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Am J Geriatr Pharmacother 10:381-9. 2012

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the international collaboration on mild traumatic brain injury prognosis
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, and the Edmond J Safra Program in Parkinson s Research, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada Electronic address
    Arch Phys Med Rehabil 95:S238-44. 2014
    ..To synthesize the best available evidence on the risk of Parkinson's disease (PD) after mild traumatic brain injury (MTBI)...
  2. doi request reprint Measuring mild cognitive impairment in patients with Parkinson's disease
    Connie Marras
    Toronto Western Hospital Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Research, Toronto, Ontario, Canada
    Mov Disord 28:626-33. 2013
    ..Other tests recommended by the Task Force Level 1 criteria may represent better choices, and these should be the subject of future research...
  3. pmc Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples
    Connie Marras
    Toronto Western Hospital Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
    Neurology 78:1016-24. 2012
    ....
  4. doi request reprint Dihydropyridine calcium channel blockers and the progression of parkinsonism
    Connie Marras
    Division of Neurology, Toronto Western Hospital, and University of Toronto, Toronto, Ontario, Canada
    Ann Neurol 71:362-9. 2012
    ..A study was undertaken to test the association between dihydropyridine calcium channel blocker use and the time to important milestones of disease progression among patients with parkinsonism...
  5. doi request reprint Antipsychotics and mortality in Parkinsonism
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, ON, Canada
    Am J Geriatr Psychiatry 20:149-58. 2012
    ..The use of antipsychotic medications is associated with an increased risk of death in older adults with dementia. The risk of death in patients with preexisting parkinsonism who receive antipsychotic drugs is not known...
  6. doi request reprint Genetics meets environment: evaluating gene-environment interactions in neurologic diseases
    Connie Marras
    Toronto Western Hospital, University of Toronto, Ontario, Canada
    Semin Neurol 31:553-61. 2011
    ..Collaborations between genetics and environmental experts will be crucial to understand the complex relationships...
  7. pmc Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers
    C Marras
    Toronto Western Hospital, Edmond J Safra Program in Parkinson s Disease, Toronto, ON M5T 2S8 Canada
    Neurology 77:325-33. 2011
    ..Using a family study design, we describe the motor and nonmotor phenotype in probands with LRRK2 G2019S mutations and family members and compare these individuals to patients with idiopathic Parkinson disease (iPD) and unrelated controls...
  8. doi request reprint Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 26:608-13. 2011
    ..We suspect that individuals employed full time may have a lower threshold for requiring dopaminergic therapy because of occupational demands...
  9. doi request reprint Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease
    William Reginold
    Toronto Western Hospital, Toronto, Ont, Canada
    Dement Geriatr Cogn Disord 36:67-75. 2013
    ..To assess the impact of mild cognitive impairment (MCI) or cognitive decline on health-related quality of life (HR-QOL) in Parkinson's disease (PD)...
  10. doi request reprint Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Am J Geriatr Pharmacother 10:381-9. 2012
    ..There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings...
  11. doi request reprint The pill questionnaire in a nondemented Parkinson's disease population
    William Reginold
    Toronto Western Hospital Movement Disorders Centre, and the Edmond J Safra Program in Parkinson s Disease, Toronto, Ontario, Canada
    Mov Disord 27:1308-11. 2012
    ..However, inaccurate medication reporting is associated with deficits spanning many cognitive domains and should alert a clinician to a higher likelihood of cognitive impairment...
  12. doi request reprint A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 24:2370-8. 2009
    ..This may relate to changes in philosophies with respect to starting treatment for Parkinson's disease, but the factors underlying this change remain to be elucidated...
  13. ncbi request reprint Pergolide associated cardiac valvulopathy based on Ontario administrative data
    Cindy Zadikoff
    Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Neurology, Toronto, Ontario, Canada
    Can J Neurol Sci 35:173-8. 2008
    ....
  14. ncbi request reprint Antipsychotic use in older adults with Parkinson's disease
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, Canada
    Mov Disord 22:319-23. 2007
    ..Typical antipsychotics are still commonly being chosen as first-line agents for older patients, indicating a need for interventions to improve practice...
  15. doi request reprint Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study
    Nathan Herrmann
    Department of Psychiatry, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Drugs Aging 30:19-22. 2013
    ....
  16. ncbi request reprint New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice
    Kenneth I Shulman
    Dept of Psychiatry and the Institute for Clinical Evaluative Sciences, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    Am J Geriatr Psychiatry 13:299-304. 2005
    ....
  17. doi request reprint LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation
    Connie Marras
    Movement Disorders Centre, Toronto Western Hospital, Toronto, Canada
    Neurobiol Aging 31:721-2. 2010
    ..In the combined mutation carriers the age at onset and clinical course was highly variable and not always younger than in the carriers of LRRK2 G2019S mutations alone...
  18. ncbi request reprint Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  19. doi request reprint Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable
    Andrea Gruneir
    Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
    Pharmacoepidemiol Drug Saf 20:221-8. 2011
    ....
  20. ncbi request reprint Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses
    Tiago A Mestre
    From the Movement Disorders Centre and Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, University Health Network, Division of Neurology T A M, C M, A E L, the Department of Paediatrics and Institute of Health Policy, Management and Evaluation P S, the Department of Public Health Sciences G T, and the Department of Medicine T A M, C M, G T, A E L, University of Toronto and the Department of Pediatrics P S, Mount Sinai Hospital, Toronto T A M is currently with the Parkinson s Disease and Movement Disorders Clinic, Division of Neurology, Ottawa Hospital, University of Ottawa
    Neurology 82:1402-9. 2014
    ..To study the impact of negative expectation related to receiving a placebo (the "lessebo effect") on efficacy outcome measures of symptomatic treatments in Parkinson disease (PD)...
  21. ncbi request reprint Atypical antipsychotics and parkinsonism
    Paula A Rochon
    Institute for Clinical Evaluative Sciences, Kunin Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Arch Intern Med 165:1882-8. 2005
    ..This has not been well documented. We compared the risk of development of incident parkinsonism among older adults dispensed atypical relative to typical antipsychotics...
  22. pmc Protocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findings
    Carol Cancelliere
    Division of Health Care and Outcomes Research, Toronto Western Research Institute, University Health Network, Ontario, Canada
    Syst Rev 1:17. 2012
    ..Finally, we will identify gaps in the literature, and make recommendations for future research...
  23. doi request reprint Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
    Margarita Pondal
    Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada
    J Neurol Neurosurg Psychiatry 84:130-5. 2013
    ....
  24. pmc Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study
    Sudeep S Gill
    Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue, Toronto, ON, Canada
    BMJ 330:445. 2005
    ..To compare the incidence of admissions to hospital for stroke among older adults with dementia receiving atypical or typical antipsychotics...
  25. doi request reprint The curious case of phenocopies in families with genetic Parkinson's disease
    Christine Klein
    Morton and Gloria Shulman Movement Disorders Center and the Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 26:1793-802. 2011
    ....
  26. doi request reprint Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment
    Leigh Christopher
    1 Morton and Gloria Shulman Movement Disorder Unit and E J Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto, Ontario, M5T 2S8, Canada
    Brain 137:565-75. 2014
    ..Furthermore, these findings suggest a crucial and direct role for dopaminergic modulation in the insula in facilitating cognitive function. ..
  27. ncbi request reprint Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians
    Tiago A Mestre
    Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, University Health Network and Division of Neurology, University of Toronto, 399 Bathurst Street, MC 7 402, Toronto, ON M5T 2S8, Canada Electronic address
    Parkinsonism Relat Disord 20:608-12. 2014
    ..There is a need to bring physicians and patients with PD closer to a shared vision of the problem reluctance to start medication. ..
  28. doi request reprint Parkinson's disease subtypes: lost in translation?
    Connie Marras
    Toronto Western Hospital, Movement Disorders Centre, 399 Bathurst St 7 MCL, Toronto, ON M5T 2S8, Canada
    J Neurol Neurosurg Psychiatry 84:409-15. 2013
    ....
  29. ncbi request reprint Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 19:22-8. 2004
    ..We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients...
  30. ncbi request reprint Predicting motor decline and disability in Parkinson disease: a systematic review
    Connie Marras
    Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada
    Arch Neurol 59:1724-8. 2002
    ..The clinical course of Parkinson disease (PD) varies from patient to patient. A number of studies investigating predictors of prognosis in patients with PD have been performed...
  31. doi request reprint Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy
    William Reginold
    Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson s Disease, Toronto Western Hospital, Canada Department of Medical Imaging, Toronto Western Hospital, The Joint Department of Medical Imaging, and the University of Toronto, Canada Electronic address
    Parkinsonism Relat Disord 20:222-5. 2014
    ..However, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are progressive diseases. This study assessed the value of longitudinal MRI in characterizing the time course of the degenerative process...
  32. doi request reprint Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain
    Connie Marras
    Toronto Western Hospital, University Health Network and University of Toronto, Ontario, Canada
    Neurology 70:1996-2003. 2008
    ..In this article, we highlight important changes in our understanding of PD in six general categories: definition, etiology, pathology, pathogenesis, clinical features, and therapeutics...
  33. ncbi request reprint Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings
    Connie Marras
    Toronto Western Hospital, Movement Disorders Centre, 7 McLaughlin, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    Expert Rev Neurother 4:985-93. 2004
    ..Currently, neuroimaging techniques that reflect function of the dopaminergic system are the most promising biomarkers but still require additional validation...
  34. ncbi request reprint Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia
    Asha Kishore
    Division of Neurology, Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 22:328-33. 2007
    ..This observation also highlights the need to perform tasks of bradykinesia in one limb at a time for best accuracy...
  35. ncbi request reprint Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker
    Naomi P Visanji
    Morton and Gloria Shulman Movement Disorders Centre and the Edmund J Safra Program in Parkinson s Disease, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 29:444-50. 2014
    ....
  36. doi request reprint Improvement of apathy after levofloxacin treatment: an N-of-1 study
    Melissa Jo Armstrong
    Department of Medicine Neurology, University of Toronto, Toronto, ON, Canada
    Neurologist 18:146-8. 2012
    ..We sought to determine whether this effect could be objectively supported and replicated outside the context of infection...